Genfit Tortures Fatty Liver Drug To Extract Positive Results From Failed Study

LILLE, France (TheStreet) -- Torture a prisoner long enough and he'll tell you what you want to hear. Clinical trials are similarly vulnerable. Just ask Genfit , which put its fatty liver drug candidate GFT505 through the statistical equivalent of waterboarding and sleep deprivation to extract the desired result from a mid-stage study: The drug works! But GFT505 achieved the primary endpoint of the study -- clearance of nonalcoholic steatohepatitis (NASH) -- only after excluding placebo patients who responded really well.

BING NEWS:
  • Genfit's French Fans Fume Following Failure of Fatty Liver Drug
    French investors holding shares of Genfit are having trouble coping with the failure of the company's fatty liver disease drug GFT505 ... yet GFT505 failed to do so. Only after Genfit threw ...
    03/31/2015 - 1:51 am | View Link
  • More

 

Welcome to Wopular!

Welcome to Wopular

Wopular is an online newspaper rack, giving you a summary view of the top headlines from the top news sites.

Senh Duong (Founder)
Wopular, MWB, RottenTomatoes

Subscribe to Wopular's RSS Fan Wopular on Facebook Follow Wopular on Twitter Follow Wopular on Google Plus

MoviesWithButter : Our Sister Site

More Business News